The spectrum ranges from the development of biomarkers to monitor new therapeutics (phase I / II studies) to 'proof of concept' and 'investigator-induced' phase I / II studies of innovative immunotherapeutic approaches based on new pathogenetic findings.

In addition to the close networking with the other research groups of the institute, there is a close collaboration with clinical partners, in particular with the interdisciplinary clinical research groups located at the institute (Nephrology / transplantation medicine, intensive care, dermatology), as well as biotech companies, clinical research organisations (CRO Charité, Parexel) and the pharmaceutical industry (Bayer Schering Pharma, Biogen, Novartis, Nycomed, Roche, Johnson / Johnson, etc.).

To top

Immunmonitoring

Please click on the following picture to learn more about "Immunmonitoring at the Institute for Medical Immunology.

  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".
  • Grafik zum Thema "Immunmonitoring am Institut für Medizinische Immunologie".

To top

Research database

For more details please use the Charité undefinedresearch database.

Contact IMI

Director:
Prof. MD
Hans-Dieter Volk

Secretariat:
Petra Katz

Charité - Universitätsmedizin Berlin
Campus Virchow-Klinikum
Institutsgebäude Süd
Föhrer Str. 15 / Südstr. 2
13353 Berlin

Postal address:
Augustenburger Platz 1

t: +49 30 450 524 062
f: +49 30 450 524 932

E-Mail